Infective endocarditis

When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

ბოლო მიმოხილვა: 11 Dec 2025
ბოლო განახლება: 13 Nov 2025

შეჯამება

Definição

História e exame físico

Principais fatores diagnósticos

  • fever/chills
  • night sweats, malaise, fatigue, anorexia, weight loss, myalgias
  • weakness
  • arthralgias
  • headache
  • shortness of breath
  • meningeal signs
  • cardiac murmur
  • Janeway lesions
  • Osler nodes
  • Roth spots
Detalhes completos

Outros fatores diagnósticos

  • splinter hemorrhages
  • cutaneous infarcts
  • chest pain
  • back pain
  • palatal petechiae
Detalhes completos

Fatores de risco

  • prior history of infectious endocarditis
  • presence of artificial prosthetic heart valves
  • certain types of congenital heart disease
  • postheart transplant (patients who develop a cardiac valvulopathy)
  • immunocompromised state
  • presence of cardiac implanted electronic device or intravascular catheters (e.g., for hemodialysis)
  • acquired degenerative valve disease
  • mitral valve prolapse or bicuspid valve prolapse
  • hypertrophic cardiomyopathy
  • intravenous drug use
  • chronic Q fever
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • blood cultures
  • echocardiogram
  • CBC
  • CRP
  • serum chemistry panel with glucose
  • LFTs
  • urinalysis
  • ECG
Detalhes completos

Investigações a serem consideradas

  • rheumatoid factor
  • erythrocyte sedimentation rate
  • complement levels
  • cardiac CT
  • MRI
  • nuclear imaging and PET
  • specific tests for blood culture-negative endocarditis
Detalhes completos

Novos exames

  • mean platelet volume (MPV)
  • anti‐beta-2‐glycoprotein I antibodies
  • D-dimer and troponin I
Detalhes completos

Algoritmo de tratamento

Inicial

suspected infective endocarditis

AGUDA

native valve: confirmed endocarditis

prosthetic valve: confirmed endocarditis

CONTÍNUA

at high risk of infective endocarditis

Colaboradores

Consultores especialistas

Carl Zehner, MD

Assistant Professor of Medicine

University of Texas MD Anderson Cancer Center

Department of Cardiology

Houston

TX

Declarações

CZ declares that he has no competing interests.

Agradecimentos

Dr Carl Zehner would like to gratefully acknowledge Dr Ammara Mushtuq, Dr Tracey Keteepe-Arachi, Dr Aneil Malhotra, Dr Michael Papadakis, Professor Sanjay Sharma, Dr Jason C. Schultz, Dr Nisha K. Lassi, and Dr Nandan S. Anavekar, previous contributors to this topic.

Declarações

TKA, MP, SS, JCS, NKL, and NSA declare that they have no competing interests. AMu declares that she is Principal Investigator on a grant from Merck on ceftolozane-tazobactam, writer for the Lancet family of journals, question writer for Blueprint Test preparations, and a peer-reviewer for Clinical Overviews, Elsevier (topics influenza and HIV). AMa is an author of a number of references cited in this topic.

Revisores

Vandana Desai, MD

Professor of Pediatrics

SMIMER Hospital

Gujarat

India

Declarações

VD declares that she has no competing interests.

Lucieni Oliveira Conterno, MD, PhD

Director

Clinical Epidemiology Unit

Marilia Medical School

Sao Paulo

Brazil

Disclosures

LOC declares that she has no competing interests.

Andrew Wang, MD

Associate Professor of Medicine

Director, Cardiovascular Disease Fellowship Program

Duke University Medical Center

Durham

NC

Disclosures

AW declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86.Full text  Abstract

Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042.Full text  Abstract

Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021 Feb 2;143(5):e72-227.Full text  Abstract

Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021 May 18;143(20):e963-78.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Infective endocarditis images
  • Differentials

    • Rheumatic fever
    • Atrial myxoma
    • Libman-Sacks endocarditis
    More Differentials
  • Guidelines

    • Blood culture-negative endocarditis
    • 2023 ESC guidelines for the management of endocarditis
    More Guidelines
  • Videos

    Venepuncture and phlebotomy: animated demonstration

    How to perform an ECG: animated demonstration

    More videos
  • Patient information

    Endocarditis

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer